MADRID (Reuters) – Spain’s Pharma Mar said on Thursday that the European Society of Medical Oncology had included its Lurbinectedin drug as a treatment option for small-cell lung cancer patients in its clinical practice guidelines.
Lurbinectedin was approved by Europe’s drug regulator to treat small-cell lung cancer in 2019 and by the U.S. FDA last June.
(Reporting by Nathan Allen and Aida Pelaez-Fernandez, editing by Andrei Khalip)
